STOCK TITAN

Brainsway Ltd. (BWAY) Financials

BWAY NASDAQ
FY2025 annual
Revenue $52.2M +27.3% YoY
Net Income $7.6M +159.3% YoY
EPS (Diluted) $0.18 +260.0% YoY
Operating Cash Flow $17.5M +69.8% YoY
Market Cap $341.3M as of Nov 20, 2026
Price / Sales 6.5x on $52.2M revenue, FY2025
Price / Earnings 45.1x on $7.6M net income, FY2025
Price / Book 4.7x on $73.2M equity, Q4 FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD FYE December

Newest figures come from the 20-F for FY2025, filed Apr 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BWAY SEC filings page.

Brainsway Ltd. (BWAY) reported $52.2M in revenue for fiscal year 2025, up 27.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).

Rhea AI BWAY FY2025

Profitability is scaling faster than sales, but growth is absorbing inventory and reducing short-term balance-sheet flexibility.

In FY2025, operating cash flow reached $17.5M against $7.6M of net income, with the supplied cash-to-income proportion at 230.9%; earnings therefore converted into more cash than reported profit alone would suggest. Meanwhile, the current ratio fell from 5.2x in FY2024 to 3.7x in FY2025 as inventory rose 47.4%, so expansion is tying up more working capital even while cash conversion improved.

Sales grew 27.3%, while cost of revenue grew 23.0%; gross profit consequently grew faster than sales. Operating margin rose 4.9 percentage points to 8.3% even as research and development spending increased, indicating the earnings step-up reflects operating scale or mix rather than simply cutting development spending.

Assets grew 20.0% while liabilities grew 25.1%, making expansion more reliant on obligations than in FY2024. Liabilities were 35.4% of assets in FY2025 versus 33.9% in FY2024; creditor claims are taking a somewhat larger share of the balance sheet.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 58 / 100
Financial Health Score (5 of 6 dimensions) 58/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Brainsway Ltd.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
34

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Brainsway Ltd. scores 34/100 on it among other operating companies.

Growth
88

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Brainsway Ltd. scores 88/100 on it among other operating companies.

Leverage
52

Brainsway Ltd. carried $0.55 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, Brainsway Ltd. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 52/100 among other operating companies measured the same way.

Liquidity
85

Brainsway Ltd. held $3.73 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 3.73. Liquidity ranks operating companies on that ratio, and Brainsway Ltd. scores 85/100 among other operating companies.

Cash Flow
n/a

Not available for Brainsway Ltd., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Returns
31

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Brainsway Ltd. scores 31/100 on it among other operating companies.

Altman Z-Score Safe
5.23

Brainsway Ltd. scores 5.23, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $341.3M against total liabilities of $40.0M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
6/8

Brainsway Ltd. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Cash-Backed
2.31x

For every $1 of reported earnings, Brainsway Ltd. generates $2.31 in operating cash flow ($17.5M OCF vs $7.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk
1.96x

Brainsway Ltd. earns $1.96 in operating income for every $1 of interest expense ($4.3M vs $2.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$52.2M
YoY+27.3%
5Y CAGR+18.8%

Brainsway Ltd. generated $52.2M in revenue in fiscal year 2025. This represents an increase of 27.3% from the prior year.

EBITDA
$5.0M
YoY+143.2%
5Y CAGRn/m

Brainsway Ltd.'s EBITDA was $5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 143.2% from the prior year.

Net Income
$7.6M
YoY+159.3%
5Y CAGRn/m

Brainsway Ltd. reported $7.6M in net income in fiscal year 2025. This represents an increase of 159.3% from the prior year.

EPS (Diluted)
$0.18
YoY+260.0%

Brainsway Ltd. earned $0.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 260.0% from the prior year.

Cash & Balance Sheet

Cash & Debt
$67.7M
YoY-2.4%
5Y CAGR+31.9%

Brainsway Ltd. held $67.7M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.

Shares Outstanding
39M
YoY+4.1%

Brainsway Ltd. had 39M shares outstanding in fiscal year 2025. This represents an increase of 4.1% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin
75.4%
YoY+0.9pp
5Y change-1.7pp

Brainsway Ltd.'s gross margin was 75.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the prior year.

Operating Margin
8.3%
YoY+4.9pp
5Y change+30.2pp

Brainsway Ltd.'s operating margin was 8.3% in fiscal year 2025, reflecting core business profitability. This is up 4.9 percentage points from the prior year.

Net Margin
14.5%
YoY+7.4pp
5Y change+38.9pp

Brainsway Ltd.'s net profit margin was 14.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 7.4 percentage points from the prior year.

Return on Equity
10.3%
YoY+5.7pp
5Y change+37.8pp

Brainsway Ltd.'s ROE was 10.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 5.7 percentage points from the prior year.

Capital Allocation

R&D Spending
$9.6M
YoY+33.6%
5Y CAGR+10.5%

Brainsway Ltd. invested $9.6M in research and development in fiscal year 2025. This represents an increase of 33.6% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BWAY Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BWAY annual income statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Revenue$52.2M+27.3%$41.0M+29.0%$31.8M+17.0%$27.2M-8.4%$29.7M+34.5%$22.1M-4.5%$23.1M+40.9%$16.4M+47.1%$11.1M
Cost of Revenue$12.8M+23.0%$10.4M+25.6%$8.3M+16.5%$7.1M+8.0%$6.6M+30.5%$5.1M-1.4%$5.1M+42.9%$3.6M+38.3%$2.6M
Gross Profit$39.4M+28.8%$30.6M+30.3%$23.5M+17.1%$20.0M-13.1%$23.1M+35.6%$17.0M-5.4%$18.0M+40.3%$12.8M+49.8%$8.6M
R&D Expenses$9.6M+33.6%$7.2M+7.9%$6.7M-13.2%$7.7M+20.1%$6.4M+9.8%$5.8M-26.1%$7.9M+27.9%$6.2M+15.2%$5.3M
Operating Income$4.3M+210.8%$1.4Mn/m-$5.0Mn/m-$12.7Mn/m-$5.0Mn/m-$4.8Mn/m-$8.5Mn/m-$5.1Mn/m-$6.6M
EBITDA$5.0M+143.2%$2.1Mn/m-$4.6Mn/m-$12.1Mn/m-$4.4Mn/m-$4.4Mn/m-$7.9Mn/m-$4.7Mn/m-$6.2M
Interest Expense$2.2M+45.7%$1.5M+30.9%$1.2M-21.1%$1.5Mn/m-$1.7M-625.1%$319K-77.7%$1.4M+23.7%$1.2M+321.9%$274K
Income Tax$135K-74.9%$538K+114.3%$251K-20.3%$315K+632.6%$43K-81.9%$237K-43.8%$422K+101.9%$209K+23.7%$169K
Net Income$7.6M+159.3%$2.9Mn/m-$4.2Mn/m-$13.3Mn/m-$6.5Mn/m-$5.4Mn/m-$10.3Mn/m-$6.5Mn/m-$7.1M
EPS (Basic)$0.20+122.2%$0.09-$0.13n/m-$0.40n/m-$0.21N/AN/AN/AN/A
EPS (Diluted)$0.18+260.0%$0.05-$0.13n/m-$0.40n/m-$0.21N/AN/AN/AN/A

Not reported in any period shown, so not listed: SG&A Expenses, Diluted Shares (Avg).

BWAY Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BWAY annual balance sheet
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Total Assets$113.2M+20.0%$94.3M+49.8%$63.0M-2.3%$64.5M-14.9%$75.7M+122.7%$34.0M-12.2%$38.7M+64.1%$23.6MN/A
Current Assets$83.8M+5.2%$79.7M+43.6%$55.5M-4.5%$58.1M-11.2%$65.4M+169.4%$24.3M-15.7%$28.8M+113.9%$13.5MN/A
Cash & Equivalents$67.7M-2.4%$69.3M+559.2%$10.5M-77.9%$47.6M+181.2%$16.9M-0.2%$17.0M-21.7%$21.7M+141.7%$9.0M-38.2%$14.5M
Inventory$6.5M+47.4%$4.4M+19.1%$3.7M-3.1%$3.8MN/AN/AN/AN/AN/A
Total Liabilities$40.0M+25.1%$32.0M+49.6%$21.4M+12.1%$19.1M+3.7%$18.4M+28.0%$14.4M-1.0%$14.5M-12.8%$16.6MN/A
Current Liabilities$22.5M+46.6%$15.3M+57.2%$9.8M+19.9%$8.1M-10.2%$9.1M+33.3%$6.8M+1.2%$6.7M-19.4%$8.3MN/A
Non-Current Liabilities$17.5M+5.3%$16.7M+43.2%$11.6M+6.3%$10.9M+17.1%$9.3M+23.3%$7.6M-2.8%$7.8M-6.2%$8.3MN/A
Long-Term DebtN/AN/AN/AN/AN/AN/AN/A$2.1MN/A
Total Equity$73.2M+17.4%$62.3M+49.9%$41.6M-8.4%$45.4M-20.8%$57.3M+192.0%$19.6M-18.9%$24.2M+248.4%$7.0M-45.4%$12.7M
Retained Earnings-$90.8Mn/m-$98.4Mn/m-$101.3Mn/m-$97.1Mn/m-$83.8Mn/m-$77.3Mn/m-$71.9Mn/m-$61.6MN/A

Not reported in any period shown, so not listed: Short-Term Investments, Accounts Receivable, Long-Term Investments, Goodwill.

BWAY Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BWAY annual cash flow statement
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Operating Cash Flow$17.5M+69.8%$10.3M+702.0%$1.3Mn/m-$9.8M-1204.1%$884Kn/m-$1.4Mn/m-$7.2Mn/m-$3.8Mn/m-$3.5M
Depreciation & Amortization$665K+0.8%$660K+82.3%$362K-35.1%$558K-0.4%$560K+27.9%$438K-20.4%$550K+18.8%$463K+17.5%$394K
Capital ExpendituresN/AN/AN/AN/A$2.2M-9.4%$2.5M-25.4%$3.3M+67.9%$2.0M+100.2%$985K
Free Cash FlowN/AN/AN/AN/A-$1.4Mn/m-$3.9Mn/m-$10.6Mn/m-$5.7Mn/m-$4.5M
Investing Cash Flow-$17.5M-157.6%$30.3Mn/m-$37.4M-188.7%$42.2Mn/m-$42.2Mn/m-$2.5Mn/m-$2.4Mn/m-$1.1Mn/m-$2.5M
Financing Cash Flow-$1.7M-109.4%$18.3Mn/m-$1.0Mn/m-$1.5M-103.7%$41.5Mn/m-$1.0M-104.6%$22.5Mn/m-$265K-102.4%$11.1M

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

BWAY Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BWAY annual financial ratios
MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Gross Margin75.4%+0.9pp74.6%+0.7pp73.9%+0.1pp73.8%-4.0pp77.8%+0.7pp77.1%-0.7pp77.8%-0.3pp78.1%+1.4pp76.7%
Operating Margin8.3%+4.9pp3.4%+19.0pp-15.6%+31.1pp-46.7%-29.8pp-16.9%+5.0pp-21.9%+14.8pp-36.7%-5.5pp-31.2%+28.1pp-59.3%
Net Margin14.5%+7.4pp7.1%+20.3pp-13.2%+35.9pp-49.1%-27.3pp-21.8%+2.6pp-24.4%+20.3pp-44.7%-5.2pp-39.5%+23.8pp-63.3%
Return on Equity10.3%+5.7pp4.7%+14.8pp-10.1%+19.3pp-29.4%-18.1pp-11.3%+16.2pp-27.4%+15.2pp-42.6%+50.6pp-93.2%-37.8pp-55.5%
Return on Assets6.7%+3.6pp3.1%+9.8pp-6.7%+14.0pp-20.7%-12.2pp-8.5%+7.3pp-15.8%+10.8pp-26.7%+0.8pp-27.5%N/A
Current Ratio3.73-1.5x5.19-0.5x5.68-1.5x7.14-0.1x7.22+3.6x3.57-0.7x4.29+2.7x1.62N/A
Debt-to-EquityN/AN/AN/AN/AN/AN/AN/A0.30N/A
Liabilities-to-Equity0.550.0x0.510.0x0.51+0.1x0.42+0.1x0.32-0.4x0.73+0.1x0.60-1.8x2.40N/A
Asset Turnover0.460.0x0.43-0.1x0.50+0.1x0.420.0x0.39-0.3x0.65+0.1x0.60-0.1x0.69N/A
FCF MarginN/AN/AN/AN/A-4.6%+13.1pp-17.7%+28.0pp-45.7%-10.6pp-35.0%+4.9pp-40.0%

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Brainsway Ltd. BWAY FY2025 $52.2M $7.6M 14.5% $341.3M 58/100
Cerus Corp CERS FY2025 $233.8M -$15.6M -6.7% $373.6M 35/100
Avita Medical, Inc. RCEL FY2025 $71.6M -$48.6M -67.8% $480.7M 48/100
908 Devices Inc. MASS FY2025 $56.2M $19.5M 34.7% $360.5M 43/100
Viemed Healthcare, Inc. VMD FY2025 $270.3M $14.9M 5.5% $322.8M 63/100
SS Innovations International Inc. SSII FY2025 $42.5M -$12.1M -28.5% $254.9M 41/100

Frequently Asked Questions

Brainsway Ltd. (BWAY) reported $52.2M in total revenue for fiscal year 2025. This represents a 27.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Brainsway Ltd. (BWAY) revenue grew by 27.3% year-over-year, from $41.0M to $52.2M in fiscal year 2025.

Yes, Brainsway Ltd. (BWAY) reported a net income of $7.6M in fiscal year 2025, with a net profit margin of 14.5%.

Brainsway Ltd. (BWAY) reported diluted earnings per share of $0.18 for fiscal year 2025. This represents a 260.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Brainsway Ltd. (BWAY) had EBITDA of $5.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Brainsway Ltd. (BWAY) had a gross margin of 75.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Brainsway Ltd. (BWAY) had an operating margin of 8.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Brainsway Ltd. (BWAY) had a net profit margin of 14.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Brainsway Ltd. (BWAY) has a return on equity of 10.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Brainsway Ltd. (BWAY) generated $17.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Brainsway Ltd. (BWAY) had $113.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Brainsway Ltd. (BWAY) invested $9.6M in research and development during fiscal year 2025.

Brainsway Ltd. (BWAY) had 39M shares outstanding as of fiscal year 2025.

Brainsway Ltd. (BWAY) had a current ratio of 3.73 as of fiscal year 2025, which is generally considered healthy.

Brainsway Ltd. (BWAY) had a liabilities-to-equity ratio of 0.55 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Brainsway Ltd. (BWAY) had a return on assets of 6.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Brainsway Ltd. (BWAY) trades at 45.1x earnings, its market capitalization divided by $7.6M net income, FY2025. The market capitalization is $341.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Brainsway Ltd. (BWAY) trades at 6.5x sales, its market capitalization divided by $52.2M revenue, FY2025. The market capitalization is $341.3M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Brainsway Ltd. (BWAY) has an Altman Z-Score of 5.23, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Brainsway Ltd. (BWAY) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Brainsway Ltd. (BWAY) has an earnings quality ratio of 2.31x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Brainsway Ltd. (BWAY) has an interest coverage ratio of 1.96x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Brainsway Ltd. (BWAY) scores 58 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Brainsway Ltd. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top